Vivoryon Therapeutics NV
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany. Show More...
-
Website https://www.vivoryon.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.71 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -2.22 -2.55 -1.35 -2.3 -1.93 -1.78 -0.96 -0.94 -0.62 -0.62 Dividends EUR Payout Ratio % * Shares Mil 7.0 7.0 7.0 5.0 7.0 8.0 8.0 8.0 13.0 13.0 Book Value Per Share * EUR -1.17 1.34 1.25 1.46 0.61 0.3 2.14 Free Cash Flow Per Share * EUR -1.03 -2.12 -1.79 -1.69 -1.04 -0.51 Return on Assets % -93.03 -128.67 -121.24 -82.12 -62.31 -62.81 -48.35 -104.48 -31.35 -31.35 Financial Leverage (Average) 1.28 1.86 1.34 1.36 1.37 1.21 3.29 1.07 1.07 Return on Equity % -119.98 -184.34 -194.72 -84.13 -85.46 -63.31 -152.41 -35.64 -35.64 Return on Invested Capital % -119.76 -181.68 -302.85 -131.83 -83.44 -84.76 -70.03 -151.64 -34.51 -34.51 Interest Coverage -199.86 -30.98 -83.84 -54.52 -119.58 -120.85 -758.25 -187.71 -71.44 -71.44 Current Ratio 3.52 2.52 0.64 4.65 4.42 4.32 16.01 4.13 48.79 48.79 Quick Ratio 3.3 2.19 0.62 4.59 4.36 4.27 15.41 3.93 44.98 44.98 Debt/Equity 0.010 0.010